Apafant

Today, in this article we are going to delve into the topic of Apafant. This is a topic that has sparked the interest of many people in recent times, and is essential to understanding key aspects of our society. Apafant has a profound impact on our daily lives, influencing our decisions, beliefs and lifestyle. Throughout this text, we will explore the different dimensions of Apafant, from its history to its relevance today. In addition, we will analyze how Apafant has evolved over time and the implications it has in various areas of society. Without a doubt, this article will be very useful for all those who wish to better understand the phenomenon of Apafant and its importance in today's world.

Apafant
Identifiers
  • 3-(4-(2-chlorophenyl)-9-methyl-6H-thienotriazolodiazepine-2-yl)-1-(4-morpholinyl)-1-propanone
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.220.442 Edit this at Wikidata
Chemical and physical data
FormulaC22H22ClN5O2S
Molar mass455.96 g·mol−1
3D model (JSmol)
  • CC1=NN=C2N1C3=C(C=C(S3)CCC(=O)N4CCOCC4)C(=NC2)C5=CC=CC=C5Cl
  • InChI=1S/C22H22ClN5O2S/c1-14-25-26-19-13-24-21(16-4-2-3-5-18(16)23)17-12-15(31-22(17)28(14)19)6-7-20(29)27-8-10-30-11-9-27/h2-5,12H,6-11,13H2,1H3
  • Key:JGPJQFOROWSRRS-UHFFFAOYSA-N

Apafant (WEB-2086, LSM-2613) is a drug which acts as a potent and selective inhibitor of the phospholipid mediator platelet-activating factor (PAF). It was developed by structural modification of the thienotriazolodiazepine sedative drug brotizolam and demonstrated that PAF inhibitory actions could be separated from activity at the benzodiazepine receptor. Apafant was investigated for several applications involving inflammatory responses such as asthma and conjunctivitis but was never adopted for medical use, however it continues to be used in pharmacology research.

References

  1. ^ Casals-Stenzel J (December 1991). "Thieno-triazolo-1,4-diazepines as antagonists of platelet-activating factor: present status". Lipids. 26 (12): 1157–1161. doi:10.1007/BF02536522. PMID 1668111. S2CID 4053407.
  2. ^ Brecht HM, Adamus WS, Heuer HO, Birke FW, Kempe ER (January 1991). "Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man". Arzneimittel-Forschung. 41 (1): 51–59. PMID 1646613.
  3. ^ Ikegami K, Hata H, Fuchigami J, Tanaka K, Kohjimoto Y, Uchida S, Tasaka K (June 1997). "Apafant (a PAF receptor antagonist) suppresses the early and late airway responses in guinea pigs: a comparison with antiasthmatic drugs". European Journal of Pharmacology. 328 (1): 75–81. doi:10.1016/s0014-2999(97)83031-2. PMID 9203572.
  4. ^ Kato M, Imoto K, Miyake H, Oda T, Miyaji S, Nakamura M (August 2004). "Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs". Journal of Pharmacological Sciences. 95 (4): 435–442. doi:10.1254/jphs.fp0040265. PMID 15286429. S2CID 34872524.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia